News
(Reuters) -Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...
Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback